Targeted therapy for breast cancer

Ali Mohamed, Kenneth Krajewski, Burcu Cakar, Cynthia X. Ma

Research output: Contribution to journalReview article

70 Citations (Scopus)

Abstract

Breast cancer is a heterogeneous group of diseases that are clinically subdivided as hormone receptor-positive, human epidermal growth factor receptor 2-positive (HER2+), and triple-negative breast cancer, to guide therapeutic interventions. Agents that target estrogen receptor (ER) and HER2 are among the most successful cancer therapeutics. However, de novo or acquired resistance is common, despite the development of newer agents against these pathways. As our understanding of tumor biology improves, novel targets are being identified. Notably, inhibitors against several pathways [including, among others, the phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR), cell-cycle regulation, heat shock protein, and epigenetic pathways] have demonstrated promising activity in clinical trials, and the mTOR-inhibitor everolimus has been approved for advanced or metastatic aromatase inhibitor-resistant ER+ breast cancer. At present, there are no established targeted agents for triple-negative breast cancer (negative ER, progesterone receptor, and HER2). Although poly(ADP-ribose) polymerase inhibitors have shown promising activity in BRCA-related cancers, its value in the treatment of triple-negative breast cancers remains to be demonstrated. In this Review, we present a basic understanding of the major targeted agents in current practice and under development for the treatment of breast cancer in the context of the three clinical subgroups.

Original languageEnglish (US)
Pages (from-to)1096-1112
Number of pages17
JournalAmerican Journal of Pathology
Volume183
Issue number4
DOIs
StatePublished - Oct 1 2013

Fingerprint

Triple Negative Breast Neoplasms
Estrogen Receptors
Breast Neoplasms
Neoplasms
Aromatase Inhibitors
1-Phosphatidylinositol 4-Kinase
Progesterone Receptors
Sirolimus
Heat-Shock Proteins
Epigenomics
Cell Cycle
Therapeutics
Clinical Trials
Hormones

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Mohamed, Ali ; Krajewski, Kenneth ; Cakar, Burcu ; Ma, Cynthia X. / Targeted therapy for breast cancer. In: American Journal of Pathology. 2013 ; Vol. 183, No. 4. pp. 1096-1112.
@article{0b08e45e59c743daaba0e0362926d745,
title = "Targeted therapy for breast cancer",
abstract = "Breast cancer is a heterogeneous group of diseases that are clinically subdivided as hormone receptor-positive, human epidermal growth factor receptor 2-positive (HER2+), and triple-negative breast cancer, to guide therapeutic interventions. Agents that target estrogen receptor (ER) and HER2 are among the most successful cancer therapeutics. However, de novo or acquired resistance is common, despite the development of newer agents against these pathways. As our understanding of tumor biology improves, novel targets are being identified. Notably, inhibitors against several pathways [including, among others, the phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR), cell-cycle regulation, heat shock protein, and epigenetic pathways] have demonstrated promising activity in clinical trials, and the mTOR-inhibitor everolimus has been approved for advanced or metastatic aromatase inhibitor-resistant ER+ breast cancer. At present, there are no established targeted agents for triple-negative breast cancer (negative ER, progesterone receptor, and HER2). Although poly(ADP-ribose) polymerase inhibitors have shown promising activity in BRCA-related cancers, its value in the treatment of triple-negative breast cancers remains to be demonstrated. In this Review, we present a basic understanding of the major targeted agents in current practice and under development for the treatment of breast cancer in the context of the three clinical subgroups.",
author = "Ali Mohamed and Kenneth Krajewski and Burcu Cakar and Ma, {Cynthia X.}",
year = "2013",
month = "10",
day = "1",
doi = "10.1016/j.ajpath.2013.07.005",
language = "English (US)",
volume = "183",
pages = "1096--1112",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "4",

}

Mohamed, A, Krajewski, K, Cakar, B & Ma, CX 2013, 'Targeted therapy for breast cancer', American Journal of Pathology, vol. 183, no. 4, pp. 1096-1112. https://doi.org/10.1016/j.ajpath.2013.07.005

Targeted therapy for breast cancer. / Mohamed, Ali; Krajewski, Kenneth; Cakar, Burcu; Ma, Cynthia X.

In: American Journal of Pathology, Vol. 183, No. 4, 01.10.2013, p. 1096-1112.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Targeted therapy for breast cancer

AU - Mohamed, Ali

AU - Krajewski, Kenneth

AU - Cakar, Burcu

AU - Ma, Cynthia X.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Breast cancer is a heterogeneous group of diseases that are clinically subdivided as hormone receptor-positive, human epidermal growth factor receptor 2-positive (HER2+), and triple-negative breast cancer, to guide therapeutic interventions. Agents that target estrogen receptor (ER) and HER2 are among the most successful cancer therapeutics. However, de novo or acquired resistance is common, despite the development of newer agents against these pathways. As our understanding of tumor biology improves, novel targets are being identified. Notably, inhibitors against several pathways [including, among others, the phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR), cell-cycle regulation, heat shock protein, and epigenetic pathways] have demonstrated promising activity in clinical trials, and the mTOR-inhibitor everolimus has been approved for advanced or metastatic aromatase inhibitor-resistant ER+ breast cancer. At present, there are no established targeted agents for triple-negative breast cancer (negative ER, progesterone receptor, and HER2). Although poly(ADP-ribose) polymerase inhibitors have shown promising activity in BRCA-related cancers, its value in the treatment of triple-negative breast cancers remains to be demonstrated. In this Review, we present a basic understanding of the major targeted agents in current practice and under development for the treatment of breast cancer in the context of the three clinical subgroups.

AB - Breast cancer is a heterogeneous group of diseases that are clinically subdivided as hormone receptor-positive, human epidermal growth factor receptor 2-positive (HER2+), and triple-negative breast cancer, to guide therapeutic interventions. Agents that target estrogen receptor (ER) and HER2 are among the most successful cancer therapeutics. However, de novo or acquired resistance is common, despite the development of newer agents against these pathways. As our understanding of tumor biology improves, novel targets are being identified. Notably, inhibitors against several pathways [including, among others, the phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR), cell-cycle regulation, heat shock protein, and epigenetic pathways] have demonstrated promising activity in clinical trials, and the mTOR-inhibitor everolimus has been approved for advanced or metastatic aromatase inhibitor-resistant ER+ breast cancer. At present, there are no established targeted agents for triple-negative breast cancer (negative ER, progesterone receptor, and HER2). Although poly(ADP-ribose) polymerase inhibitors have shown promising activity in BRCA-related cancers, its value in the treatment of triple-negative breast cancers remains to be demonstrated. In this Review, we present a basic understanding of the major targeted agents in current practice and under development for the treatment of breast cancer in the context of the three clinical subgroups.

UR - http://www.scopus.com/inward/record.url?scp=84884561721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884561721&partnerID=8YFLogxK

U2 - 10.1016/j.ajpath.2013.07.005

DO - 10.1016/j.ajpath.2013.07.005

M3 - Review article

C2 - 23988612

AN - SCOPUS:84884561721

VL - 183

SP - 1096

EP - 1112

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 4

ER -